Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Torrent Pharmaceuticals Ltd, d/b/a Torrent Pharma, is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #3 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 29 Nov 2024 | Jinesh Shah, Designated Person (in capacity of trustee of Jinesh Trust) | Other | Buy | 0 | ₹0 |
| 20 Oct 2021 | Shailesh Haribhakti | Director | Pledge | 0 | ₹1.01 Cr |
| 25 Jun 2021 | Shailesh Haribhakti | Director | Buy | 0 | ₹0 |
| 3 Jun 2021 | Shailesh Haribhakti | Director | Buy | 0 | ₹0 |
| 2 Jun 2021 | Shailesh Haribhakti | Director | Buy | 0 | ₹0 |
| 1 Jun 2021 | Shailesh Haribhakti | Director | Buy | 0 | ₹0 |
| 7 Jan 2021 | Harish Guttikar | Other | Buy | 0 | ₹0 |
| 7 Jan 2021 | Harish Guttikar | Other | Sell | 0 | ₹0 |
| 3 Oct 2020 | Karan Shah | Employee / designated person | Buy | 0 | ₹0 |
| 3 Oct 2020 | Karan Shah | Employee / designated person | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 23 Jan 2025 | UBS PRINCIPAL CAPITAL ASIA LIMITED | Block | Sell | 44,810 | 3252.1000 | NSE |
| 23 Jan 2025 | UBS AG | Block | Buy | 44,810 | 3252.1000 | NSE |
| 30 Oct 2024 | TORRENT INVESTMENTS PRIVATE LIMITED | Bulk | Sell | 4,972,020 | 3104.4000 | BSE |
| 7 Mar 2024 | SEB FUND 3 SEB PENSION FUND | Block | Sell | 63,294 | 2691.2000 | NSE |
| 7 Mar 2024 | SEB ASIENFOND EX JAPAN | Block | Buy | 63,294 | 2691.2000 | NSE |
| 25 Jan 2024 | MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND | Block | Buy | 3,883 | 2507.0500 | BSE |
| 25 Jan 2024 | MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND | Block | Buy | 4,356 | 2507.0500 | BSE |
| 25 Jan 2024 | MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND | Block | Buy | 47,322 | 2507.0500 | BSE |
| 25 Jan 2024 | BNP PARIBAS ARBITRAGE | Block | Sell | 55,561 | 2507.0500 | BSE |
| 25 Jan 2024 | SOCIETE GENERALE | Block | Buy | 474,629 | 2507.0500 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 29 May 2026 | Dividend - Rs 9 Per Share | 9.0000 | 29 May 2026 |
| 18 Feb 2026 | Interim Dividend - Rs 29 Per Share | 29.0000 | 19 Feb 2026 |
| 20 Jun 2025 | Dividend - Rs 6 Per Share | 6.0000 | 20 Jun 2025 |
| 31 Jan 2025 | Interim Dividend - Rs 26 Per Sh | 26.0000 | 1 Feb 2025 |
| 21 Jun 2024 | Dividend - Rs 6 Per Share | 6.0000 | 21 Jun 2024 |
| 12 Feb 2024 | Interim Dividend - Rs 22 Per Share | 22.0000 | 12 Feb 2024 |
| 23 Jun 2023 | Dividend - Rs 8 Per Share | 8.0000 | 23 Jun 2023 |
| 3 Feb 2023 | Interim Dividend - Rs 14 Per Share | 14.0000 | 3 Feb 2023 |
| 2 Feb 2022 | Interim Dividend - Rs 25 Per Share | 25.0000 | 3 Feb 2022 |
| 17 Jun 2021 | Dividend - Rs 15 Per Share | 15.0000 | 18 Jun 2021 |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 8 Jul 2022 | BONUS | Bonus 1:1 |
| 23 Jul 2013 | BONUS | Bonus 1:1 |
| 15 Jun 2007 | AGM | Agm |
| 23 Mar 2007 | OTHER | Int Div-Rs.3/- Per Share Purpose Revised |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 30 Jul 2026 | Financial Results | Yes |
| 22 May 2026 | Financial Results/Dividend/Fund Raising/Other business matters | Yes |
| 13 Feb 2026 | Financial Results/Dividend | Yes |
| 5 Jan 2026 | Fund Raising | — |
| 7 Nov 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 100, NIFTY 100, NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY NEXT 50, NIFTY NEXT 50, NIFTY PHARMA, NIFTY PHARMA, NIFTY100 ALPHA 30, NIFTY100 ALPHA 30
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
